Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma

Volker L. Reichardt, Craig Y. Okada, Keith E. Stockerl-Goldstein, Bjarne Bogen, Ronald Levy

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


With conventional therapy, multiple myeloma (MM) has a poor prognosis. During the last few years, it has become clear that high-dose chemotherapy with autologous stem cell support can increase overall survival of MM patients, but further improvement in outcome is desperately needed. The monoclonal immunoglobulin (Ig) produced by the MM cells called idiotypes (Id) is a tumor-specific antigen due to unique antigenic determinants that are localized in the variable regions of the Ig molecule. Conceivably, Id immunization of MM patients in complete remission could further increase survival. Here we renew the scientific basis for such Id immunization.

Original languageEnglish (US)
Pages (from-to)157-163
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Issue number3
StatePublished - Aug 1997
Externally publishedYes


  • High-dose therapy
  • Idiotypic vaccination
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma'. Together they form a unique fingerprint.

Cite this